ArticleBMC cancer2022

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.

Maartje W Rohaan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.